Richard van Oostrom to Join Board of TransMedics, Inc., Makers of the First Device to Maintain Functioning Organs Outside the Body

Sep 26, 2006, 01:00 ET from TransMedics, Inc.

    ANDOVER, Mass., Sept. 26 /PRNewswire-FirstCall/ -- TransMedics, Inc., a
 privately held medical device company founded in 1998 to address the unmet
 need for better, more effective organ transplant technologies, announced
 today that Richard van Oostrom, formerly of Guidant Corporation, has joined
 the company's board of directors. This appointment marks the latest step in
 the evolution of the TransMedics board with the addition of
 industry-experienced, non-investor board members.
     "We are delighted that Mr. van Oostrom has joined our board at this
 pivotal time in TransMedics' history," said Dr. Waleed Hassanein, president
 and CEO of TransMedics. "As the European phase of the PROTECT heart trial
 of our Organ Care System continues to progress, we welcome his expert input
 as we move forward in our efforts to expand the reach of the trial and
 towards our near term goal of product commercialization in Europe."
     Mr. Van Oostrom brings more than 30 years of experience in the medical
 device market to TransMedics. He is a former member of the executive board
 of Guidant Corporation, past president of its European operations, and was
 involved in the formation of Guidant and its subsequent IPO on the New York
 Stock Exchange in 1994. He served as Chairman of the European Board till
 mid-2006, when Guidant was acquired by Boston Scientific.
     Previously, van Oostrom was in charge of the Medical Devices and
 Diagnostic Division of Eli Lilly and Company in Europe, and was based in
 London, England. Prior to that, he held executive positions at Eli Lilly in
 the US, Canada, Italy, Germany and the UK. "The TransMedics Organ Care
 System is a truly unique lifesaving technology that represents a real
 breakthrough in transplantation," said Mr. van Oostrom. "I strongly believe
 in the capability and leadership of TransMedics, and I am honored to become
 a part of the visionary work being done by Dr. Hassanein and his team. I
 look forward to assisting as they expand their trials and as they work
 towards commercialization of this remarkable device."
     A native of the Netherlands, Mr. van Oostrom studied economics in the
 Netherlands and received a Master of Business Administration from the
 University of Texas in 1970. In the last eight years he has been involved
 as board member in several medical ventures in Europe and Israel.
     About TransMedics, Inc.
     Headquartered in Andover, Massachusetts, TransMedics is a privately
 held medical device company founded in 1998 to address the unmet need for
 better, more effective organ transplant technologies. The Company has
 developed the first and only system that allows a new type of organ
 transplant, called a living organ transplant. This breakthrough,
 investigational technology, called an Organ Care System, is designed to
 maintain organs in a warm functioning state outside of the body during
 transport from organ donor to recipient. The goal of TransMedics'
 technology is to improve outcomes and increase organ availability for the
 growing population of patients with end-stage organ failure in need of a
 transplant, bridging the ever-widening gap between the number of organs and
 the number of recipients awaiting transplants. TransMedics' mission is to
 enable more patients with end-stage organ failure to benefit from the
 accepted medical standard of care -- successful transplantation. The
 TransMedics Organ Care System is designed to help to improve the health of
 organs being transplanted as well as increase the number of organs
 available, improving outcomes, and reducing recovery time, hospital stays
 and reliance on ongoing medical therapies. For more information, visit

SOURCE TransMedics, Inc.